{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT03999853",
            "orgStudyIdInfo": {
                "id": "19-006035"
            },
            "organization": {
                "fullName": "Mayo Clinic",
                "class": "OTHER"
            },
            "briefTitle": "Butyrate Adjuvant Therapy for Type 1 Diabetes",
            "officialTitle": "Colonic Delivery of Butyrate to Improve Insulin Sensitivity and Lower Triglycerides in Type 1 Diabetes Subjects",
            "therapeuticArea": [
                "Endocrinology"
            ],
            "study": "butyrate-adjuvant-therapy-for-type-diabetes"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-07-28",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-10",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2019-06-25",
            "studyFirstSubmitQcDate": "2019-06-25",
            "studyFirstPostDateStruct": {
                "date": "2019-06-27",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-09",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-10",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "PRINCIPAL_INVESTIGATOR",
                "investigatorFullName": "Adrian Vella",
                "investigatorTitle": "Consultant",
                "investigatorAffiliation": "Mayo Clinic"
            },
            "leadSponsor": {
                "name": "Mayo Clinic",
                "class": "OTHER"
            },
            "collaborators": [
                {
                    "name": "BioKier Inc.",
                    "class": "INDUSTRY"
                },
                {
                    "name": "Juvenile Diabetes Research Foundation",
                    "class": "OTHER"
                }
            ]
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "The investigators are interested to evaluate the effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy on metabolic control in type 1 diabetes (TID) subjects.",
            "detailedDescription": "This study will test effect of BKR-017 (colon-targeted 500 mg butyrate tablets) as adjuvant therapy in type 1 diabetes (TID) Subjects on metabolic control in this population. Insulin sensitivity, glucose control (variability) and triglycerides will be measured after 8 weeks of treatment and compared to baseline."
        },
        "conditionsModule": {
            "conditions": [
                "Type1diabetes"
            ],
            "keywords": [
                "Butyrate"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "interventionModelDescription": "BKR-017: Delayed release butyrate which promotes endogenous incretin secretion to determine if this improves insulin action",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 20,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Conventional Therapy / Butyrate",
                    "type": "EXPERIMENTAL",
                    "description": "Subjects will be receiving usual therapy for the first study period (approx 1 month) then 500 mg Butyrate tablets to be taken at a dose of 1.5 g (3 tablets) twice daily (BID) for approx 2 months",
                    "interventionNames": [
                        "Drug: BKR-017"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "BKR-017",
                    "description": "BKR-017",
                    "armGroupLabels": [
                        "Conventional Therapy / Butyrate"
                    ],
                    "otherNames": [
                        "Butyrate tablets"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Insulin sensitivity",
                    "description": "Change in Insulin sensitivity",
                    "timeFrame": "(Day 0) to Day 28 and Day 56"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Glucose Variability and Triglycerides",
                    "description": "Changes in glucose measurements and triglycerides",
                    "timeFrame": "(Day 0) to Day 28 and Day 56"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. All type 1 diabetes with C-Peptide (CPR) less than 0.5 ng/mL subjects who are \\> 20 and \\<80 years of age recruited from the Mayo Clinic Endocrinology Clinic;\n2. Will also meet HbA1c level of 6.4-8.9% and BMI of \\< 30 kg/m2 at week -4.\n\nExclusion Criteria:\n\n1. Except for the use of insulin, no other treatments for T1D will be permitted.\n2. Pregnancy\n3. Inability or unwillingness of individual or legal guardian/representative to give written informed consent.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "20 Years",
            "maximumAge": "80 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Paula Giesler, BSN",
                    "role": "CONTACT",
                    "phone": "507-255-8345",
                    "email": "Giesler.Paula@mayo.edu"
                },
                {
                    "name": "Amy Zipse",
                    "role": "CONTACT",
                    "phone": "507-255-0907",
                    "email": "Zipse.Amy@mayo.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Adrian Vella, MD",
                    "affiliation": "Mayo Clinic",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "Mayo Clinic in Rochester",
                    "status": "RECRUITING",
                    "city": "Rochester",
                    "state": "Minnesota",
                    "zip": "55905",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 44.02163,
                        "lon": -92.4699
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Mayo Clinic Clinical Trials",
                    "url": "https://www.mayo.edu/research/clinical-trials"
                }
            ]
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000003920",
                    "term": "Diabetes Mellitus"
                },
                {
                    "id": "D000003922",
                    "term": "Diabetes Mellitus, Type 1"
                }
            ],
            "ancestors": [
                {
                    "id": "D000044882",
                    "term": "Glucose Metabolism Disorders"
                },
                {
                    "id": "D000008659",
                    "term": "Metabolic Diseases"
                },
                {
                    "id": "D000004700",
                    "term": "Endocrine System Diseases"
                },
                {
                    "id": "D000001327",
                    "term": "Autoimmune Diseases"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M10018",
                    "name": "Hypersensitivity",
                    "relevance": "LOW"
                },
                {
                    "id": "M7117",
                    "name": "Diabetes Mellitus, Type 1",
                    "asFound": "Type 1 Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M7115",
                    "name": "Diabetes Mellitus",
                    "asFound": "Diabetes",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11639",
                    "name": "Metabolic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M25403",
                    "name": "Glucose Metabolism Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7862",
                    "name": "Endocrine System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M4629",
                    "name": "Autoimmune Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC18",
                    "name": "Nutritional and Metabolic Diseases"
                },
                {
                    "abbrev": "BC19",
                    "name": "Gland and Hormone Related Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10365",
                    "name": "Insulin",
                    "relevance": "LOW"
                },
                {
                    "id": "M173166",
                    "name": "Insulin, Globin Zinc",
                    "relevance": "LOW"
                },
                {
                    "id": "T120",
                    "name": "Cola",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Hypo",
                    "name": "Hypoglycemic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                },
                {
                    "abbrev": "HB",
                    "name": "Herbal and Botanical"
                }
            ]
        }
    },
    "hasResults": false
}